Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Mylotarg

(MY-loh-targ)
A drug used alone or with other drugs to treat acute myeloid leukemia that is CD33 positive (expresses the protein CD33). It is used in adults and in children aged 1 month and older whose disease is newly diagnosed. It is also used in adults and in children aged 2 years and older whose disease has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Mylotarg contains a monoclonal antibody that binds to CD33, which is found on some leukemia cells. It also contains an anticancer drug, which may help kill cancer cells. Mylotarg is a type of antibody-drug conjugate. Also called gemtuzumab ozogamicin.
Search NCI's Dictionary of Cancer Terms